NASDAQ:HSIC - Henry Schein Stock Price, News, & Analysis

Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."

Henry Schein's stock split on the morning of Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly issued shares were distributed to shareholders after the closing bell on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split.

Henry Schein announced that its Board of Directors has authorized a stock buyback program on Tuesday, September 19th 2017, which permits the company to repurchase $400,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to reacquire up to 6.3% of its stock through open market purchases. Stock repurchase programs are often an indication that the company's management believes its shares are undervalued.

Henry Schein, Inc. (NASDAQ:HSIC) announced its quarterly earnings data on Tuesday, November, 6th. The company reported $1.03 earnings per share for the quarter, topping analysts' consensus estimates of $1.01 by $0.02. The firm had revenue of $3.28 billion for the quarter, compared to the consensus estimate of $3.37 billion. Henry Schein had a net margin of 3.00% and a return on equity of 20.40%. Henry Schein's revenue was up 3.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.87 earnings per share. View Henry Schein's Earnings History.

Henry Schein is scheduled to release their next quarterly earnings announcement on Tuesday, February 19th 2019. View Earnings Estimates for Henry Schein.

Henry Schein updated its FY18 earnings guidance on Tuesday, November, 6th. The company provided earnings per share (EPS) guidance of $4.06-4.14 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.12.

18 Wall Street analysts have issued 12-month target prices for Henry Schein's shares. Their predictions range from $66.00 to $102.00. On average, they expect Henry Schein's share price to reach $83.5625 in the next year. This suggests that the stock has a possible downside of 1.6%. View Analyst Price Targets for Henry Schein.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last year. There are currently 2 sell ratings, 8 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Henry Schein.

Press coverage about HSIC stock has trended somewhat negative recently, InfoTrie reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Henry Schein earned a news impact score of -1.9 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future.

Some companies that are related to Henry Schein include Boston Scientific (BSX), Celgene (CELG), HCA Healthcare (HCA), Humana (HUM), Illumina (ILMN), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Baxter International (BAX), FRESENIUS SE &/S (FSNUY), Takeda Pharmaceutical (TKPYY), Edwards Lifesciences (EW), Actelion (ALIOF), ASTELLAS PHARMA/ADR (ALPMY) and ESSILOR Intl S/S (ESLOY).

Henry Schein's stock is owned by many different of institutional and retail investors. Top institutional investors include Longview Partners Guernsey LTD (8.92%), BlackRock Inc. (6.94%), FMR LLC (5.69%), Alecta Pensionsforsakring Omsesidigt (3.24%), Atlanta Capital Management Co. L L C (1.92%) and JPMorgan Chase & Co. (1.64%). Company insiders that own Henry Schein stock include Barry J Alperin, Donald J Kabat, Gerald A Benjamin, James A Harding, Kurt P Kuehn, Lorelei Mcglynn, Mark E Mlotek, Michael Racioppi, Michael S Ettinger, Paul Brons, Paul Rose, Philip A Laskawy and Steven Paladino. View Institutional Ownership Trends for Henry Schein.

HSIC stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Alecta Pensionsforsakring Omsesidigt, Schroder Investment Management Group, JPMorgan Chase & Co., Mitsubishi UFJ Trust & Banking Corp, Longview Partners Guernsey LTD, BlackRock Inc. and Canada Pension Plan Investment Board. Company insiders that have sold Henry Schein company stock in the last year include Barry J Alperin, Mark E Mlotek and Paul Brons. View Insider Buying and Selling for Henry Schein.

HSIC stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Atlanta Capital Management Co. L L C, AXA, American Century Companies Inc., WINTON GROUP Ltd, Ancora Advisors LLC, First Trust Advisors LP and SG Americas Securities LLC. View Insider Buying and Selling for Henry Schein.

Shares of HSIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HSIC stock can currently be purchased for approximately $84.92.

Henry Schein has a market capitalization of $12.93 billion and generates $12.46 billion in revenue each year. The company earns $406.29 million in net income (profit) each year or $3.60 on an earnings per share basis. Henry Schein employs 22,000 workers across the globe.

The official website for Henry Schein is http://www.henryschein.com.

Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company can be reached via phone at 631-843-5500 or via email at [email protected]